Cargando…

1162: SINGLE-CELL IMMUNE PROFILING AND REPERTOIRE ANALYSIS OF CONVALESCENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND SARS-COV-2 ANTIBODY RESPONSE

Detalles Bibliográficos
Autores principales:	Gubatan, John Mark, Singh, Gulshan, Balabanis, Tatiana, Patel, Akshar, Sharma, Arpita, Ji, Allison R., Rogalla, Stephan, Sinha, Sidhartha R., Davis, Mark M., Habtezion, Aida
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212398/ http://dx.doi.org/10.1016/S0016-5085(22)60656-5

Ejemplares similares

SARS-CoV-2 Testing, Prevalence, and Predictors of COVID-19 in Patients with Inflammatory Bowel Disease in Northern California
por: Gubatan, John, et al.
Publicado: (2020)

Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions
por: Gubatan, John, et al.
Publicado: (2021)

Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival
por: Weingarden, Alexa R, et al.
Publicado: (2022)

Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy
por: Rubin, Samuel J S, et al.
Publicado: (2022)

113 COVID-19 PANDEMIC INCREASED HEALTHCARE UTILIZATION AMONG PATIENTS WITH FUNCTIONAL GASTROINTESTINAL DISORDERS
por: Gubatan, John Mark, et al.
Publicado: (2021)

Reply
por: Gubatan, John, et al.
Publicado: (2021)

Gut Microbiome in Inflammatory Bowel Disease: Role in Pathogenesis, Dietary Modulation, and Colitis-Associated Colon Cancer
por: Gubatan, John, et al.
Publicado: (2022)

Sa1064: IMPACT OF COVID-19 PANDEMIC ON PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A LOCAL REPORT
por: Tsipotis, Evangelos, et al.
Publicado: (2022)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

653: PATIENTS WITH INFLAMMATORY BOWEL DISEASE HAVE IMPAIRED HUMORAL BUT PRESERVED CELLULAR RESPONSES TO SARS-COV-2 MRNA VACCINATION
por: Li, Dalin, et al.
Publicado: (2022)

656: POST-VACCINATION SYMPTOMS AFTER A THIRD DOSE OF SARS-COV-2 MRNA VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Mujukian, Angela, et al.
Publicado: (2022)

Su093 GUT-BRAIN AXIS AND IRRITABLE BOWEL SYNDROME DURING SARS COV-2 PANDEMIC. A SURVEY BASED STUDY.
por: Piskorz, Maria, et al.
Publicado: (2021)

Fr497 INCIDENCE AND OUTCOMES OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD): A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Khan, Shahab R., et al.
Publicado: (2021)

Fr501 BIOLOGICS AND COVID-19 OUTCOMES IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Weissman, Simcha, et al.
Publicado: (2021)

EP1270: SEROCONVERSION IN INFLAMMATORY BOWEL DISEASE PATIENTS AFTER COVID-19 VACCINATION
por: Horvath, Miklos, et al.
Publicado: (2022)

Tu1544: HUMORAL AND T CELL RESPONSES TO COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Sa504 INCIDENCE OF INFLAMMATORY BOWEL DISEASE IN SOUTH ASIAN AND CHINESE PEOPLE: A POPULATION-BASED COHORT STUDY FROM ONTARIO, CANADA
por: Dhaliwal, Jasbir, et al.
Publicado: (2021)

Fr496 THE EFFECTS OF COMORBIDITIES ON COVID-19 OUTCOMES AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Parekh, Rajen, et al.
Publicado: (2021)

Fr500 COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS
por: Tripathi, Kartikeya, et al.
Publicado: (2021)

Fr502 INFLAMMATORY BOWEL DISEASE AND COVID-19: A LARGE INTEGRATED HEALTHCARE EXPERIENCE
por: Tashjian, Vartan C., et al.
Publicado: (2021)

Su1495: COVID-19 VACCINE HESITANCY REMAINS HIGH IN INFLAMMATORY BOWEL DISEASE PATIENTS
por: Kwon, Hyuk Joon, et al.
Publicado: (2022)

Su1491: ATTITUDES AND PREDICTORS OF COVID-19 VACCINE UPTAKE IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE
por: Zhang, Eva, et al.
Publicado: (2022)

Su1498: SAFETY OF COVID-19 VACCINATION IN INFLAMMATORY BOWEL DISEASE PATIENTS ON BIOLOGIC THERAPY
por: Garrido, Isabel, et al.
Publicado: (2022)

Sa571 EVALUATION OF MENTAL STATE AND CLINICAL SYMPTOMS OF CORONAVIRUS PANDEMIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Tani, Mizuki, et al.
Publicado: (2021)

Mo1055: COST-EFFECTIVENESS ANALYSIS OF SUBCUTANEOUS INFLIXIMAB FOR INFLAMMATORY BOWEL DISEASES IN SEQUENCIAL BIOLOGICAL TREATMENT
por: Baik, Deborah, et al.
Publicado: (2022)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Tu1547: COVID-19 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Meybodi, Mohamad Aghaie, et al.
Publicado: (2022)

Sa1053: OUTCOMES OF HOSPITALIZED COVID-19 PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONAL DATABASE STUDY
por: Melquist, Stephanie J., et al.
Publicado: (2022)

Fr509 COVID-19 OUTCOMES AMONG RACIAL AND ETHNIC MINORITY INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASES IN THE UNITED STATES
por: Agrawal, Manasi, et al.
Publicado: (2021)

Fr103 STRATIFYING THE IMPACT OF COVID-19 PANDEMIC ON THE EMOTIONAL AND PHYSICAL WELL-BEING OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE.
por: El-Dallal, Mohammed, et al.
Publicado: (2021)

Sa502 THE FIRST AND SECOND WAVE OF COVID-19 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A TEMPORAL TREND ANALYSIS
por: Kaplan, Gilaad, et al.
Publicado: (2021)

Su1489: HUMORAL IMMUNOGENICITY OF THREE SARS-COV-2 MRNA VACCINE DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Schell, Trevor, et al.
Publicado: (2022)

Fr498 NEW GASTROINTESTINAL SYMPTOMS ARE COMMON IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH COVID-19: DATA FROM AN INTERNATIONAL REGISTRY
por: Ungaro, Ryan C., et al.
Publicado: (2021)

Fr503 FEAR OF COVID-19, ALONG WITH STRESS, ANXIETY, AND DEPRESSION, IS ASSOCIATED WITH BIOLOGIC USAGE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Shah, Rishabh, et al.
Publicado: (2021)

Sa077 DOES THE LOCKDOWN DUE TO COVID-19 PANDEMIC AFFECT THE LIFESTYLE AND DISEASE ACTIVITY OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE?
por: Hosomi, Shuhei, et al.
Publicado: (2021)

Su1075: SIMILAR RISK OF INFECTION WITH SARS-COV-2 IN IMMUNOCOMPROMISED AND IMMUNOCOMPETENT PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HEALTHY CONTROLS
por: Kante, Bhaskar, et al.
Publicado: (2022)

Su1484: SEROLOGICAL RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE COHORT STUDY
por: Quan, Joshua, et al.
Publicado: (2022)

Mo1088: DIFFERENCES BETWEEN FUNCTIONAL CONSTIIPATION AND CONSTIPATION-PREDOMNANT IRRITABLE BOWEL SYNDROME WITH FOCUS PERFERCTIONISM BY STATISTICAL FACTOR ANALYSIS
por: Yamamoto, Sayuri, et al.
Publicado: (2022)

Tu1550: REAL WORLD USE AND ADVERSE EVENTS OF SARS-COV-2 VACCINATION IN GREEK PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Orfanoudaki, Eleni, et al.
Publicado: (2022)

Tu1552: PRESERVED SARS-COV-2 VACCINE CELL-MEDIATED IMMUNOGENICITY IN INFLAMMATORY BOWEL DISEASE PATIENTS ON IMMUNEMODULATING THERAPIES
por: Boland, Brigid S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6b60d0031qspc6vsmrsep5ifcs